The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

—According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive dyskinesia, ...

Tardive dyskinesia (TD) is a movement disorder. It’s a side effect of taking neuroleptic drugs. Treatment is focused on stopping the recurrence or persistence of symptoms. Tardive dyskinesia (TD) is a ...

Neurocrine Biosciences (NBIX) has kicked off a Phase 2 trial for NBI-1065890, a next generation VMAT2 inhibitor for tardive dyskinesia. This move could matter for investors following its movement ...

TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label ...

—The exact pathology of tardive dyskinesia is still unclear, but the potential genetic factors these investigators have identified may enhance the understanding, treatment, and prevention of this ...

Tardive dyskinesia, or TD, is a drug-induced movement disorder that can occur in individuals taking certain medications that block dopamine receptors in the brain. Most commonly, cases of TD are ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...